Publications
5891 Results
- Journal / Conference
- American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0605
A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group study S0605)
- Journal / Conference
- Blood 116:Abstract 589; ASH 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- E4494
R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of Intergroup E4494/C9793
- Journal / Conference
- Blood 116:abst.#415; American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- E2496
A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
- Journal / Conference
- Blood 116:abst.#591; American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0515
Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and Rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group study S0515
- Journal / Conference
- Blood 116:abst.#590; Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0433
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group protocol S0433
- Journal / Conference
- Blood 116:Abstract 6 (LBA-6); ASH late-breaking oral presentation
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0325
A randomized phase II trial of dasatinib 100 mg vs. imatinib 400 mg in newly diagnosed chronic phase (CML-CP): the S0325 intergroup trial
- Journal / Conference
- Blood 116:abst.#1038, 2010; American Society of Hematology Annual Mtg, poster
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- C9710
Clonal markers in relapsed acute promyelocytic leukemia (APL): clinicopathological associations and relation to all-trans retinoic acid (ATRA) treatment on intergroup phase III trial C9710
- Journal / Conference
- Journal of Clinical Oncology 28:15s (suppl; abstr 3616); ASCO Annual Meeting; poster
- Year
- 2010
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) - findings from the ACCENT dataset
- Journal / Conference
- Nutrition and Cancer 62(7):896-918
- Year
- 2010
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
A nutrient approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) [PMID20924966]
- Journal / Conference
- Cancer 116(24):5710-5715
- Year
- 2010
- Research Committee(s)
- Lung
- Study Number(s)
- S0124